Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia

被引:11
作者
Najarian, Dean [1 ]
Turkoz, Ibrahim [2 ,8 ]
Knight, R. Karl
Galderisi, Silvana [3 ]
Lamaison, Hector F. [4 ]
Zalitacz, Piotr [5 ]
Aravind, Suresh [2 ,7 ]
Richarz, Ute [6 ]
机构
[1] Janssen Sci Affairs LLC, Titusville, NJ USA
[2] Janssen Res & Dev LLC, Titusville, NJ USA
[3] Univ Campania Luigi Vanvitelli, Naples, Italy
[4] Natl Univ La Plata UNLP, Dept Psychiat, Buenos Aires, Argentina
[5] Gorlice Specialist Hosp, Psychiat Unit, Gorlice, Poland
[6] Cilag Int, Janssen Res & Dev, Gubelstr, Zug, Switzerland
[7] Dural Consulting LLC, St Petersburg, FL USA
[8] Janssen Res & Dev LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560 USA
关键词
Long-term efficacy; schizophrenia; long-acting injectable; open-label extension; paliperidone palmitate 6-month; ACTING INJECTABLE ANTIPSYCHOTICS; PALMITATE; RELAPSE; REHOSPITALIZATION; NONADHERENCE; MEDICATION; ADHERENCE; PLACEBO;
D O I
10.1093/ijnp/pyad028
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Paliperidone palmitate 6-month (PP6M) demonstrated noninferiority to paliperidone palmitate 3-month in preventing relapse in patients with schizophrenia in a phase 3 double-blind (DB) study (NCT03345342). Here, we report long-term efficacy and safety results from a 2-year single-arm, open-label extension (OLE; NCT04072575) of this DB study. Methods Participants who completed the DB study without relapse were enrolled and followed-up every 3 months up to 2 years. Participants received 4 PP6M gluteal injections (700/1000 mg eq.) at baseline, 6-month, 12-month, and 18-month visits. Efficacy endpoints included assessment of relapse, Positive and Negative Syndrome Scale total score, Personal and Social Performance score, and Clinical Global Impression-Severity scale change from baseline. Safety was assessed by treatment-emergent adverse events (TEAEs), physical examinations, and laboratory tests. Results Of 178 participants enrolled, 154 (86.5%) completed the OLE (mean age: 40.4 years, men: 70.8%; mean duration of PP6M exposure during OLE: 682.1 days). Overall, 7/178 (3.9%) participants relapsed between 20 and 703 days after enrolment. Mean (SD) changes from baseline to endpoint were as follows: Positive and Negative Syndrome Scale total score, 0.7 (8.22); Clinical Global Impression-Severity, 0.0 (0.51); and Personal and Social Performance Scale, 0.5 (7.47). Overall, 111/178 participants (62.4%) reported & GE;1 TEAE; most common (>5%) TEAEs were headache (13.5%) and increased blood prolactin/hyperprolactinemia (18.0%); 8/178 (4.5%) participants experienced serious TEAEs, and 6/178 (3.4%) participants withdrew due to TEAEs. No deaths were reported. Conclusions The relapse rate observed with PP6M during the 2-year OLE was low (3.9%). Clinical and functional improvements demonstrated in the DB study were maintained during OLE, and no new safety concerns were identified.
引用
收藏
页码:537 / 544
页数:8
相关论文
共 50 条
[41]   Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study [J].
Tepper, Stewart J. ;
Ashina, Messoud ;
Reuter, Uwe ;
Brandes, Jan Lewis ;
Dolezil, David ;
Silberstein, Stephen D. ;
Winner, Paul ;
Zhang, Feng ;
Cheng, Sunfa ;
Mikol, Daniel D. .
CEPHALALGIA, 2020, 40 (06) :543-553
[42]   Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study [J].
Nash, Peter ;
Coates, Laura C. ;
Kivitz, Alan ;
Mease, Philip J. ;
Gladman, Dafna D. ;
Covarrubias-Cobos, Jose A. ;
Fitzgerald, Oliver ;
Fleishaker, Dona ;
Wang, Cunshan ;
Wu, Joseph ;
Hsu, Ming-Ann ;
Menon, Sujatha ;
Fallon, Lara ;
Romero, Ana Belen ;
Kanik, Keith S. .
RHEUMATOLOGY AND THERAPY, 2020, 7 (03) :553-580
[43]   Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension [J].
Harvey, Philip D. ;
Siu, Cynthia O. ;
Hsu, Jay ;
Cucchiaro, Josephine ;
Maruff, Paul ;
Loebel, Antony .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 (11) :1373-1382
[44]   Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study [J].
Deleuran, Mette ;
Thaci, Diamant ;
Beck, Lisa A. ;
de Bruin-Weller, Marjolein ;
Blauvelt, Andrew ;
Forman, Seth ;
Bissonnette, Robert ;
Reich, Kristian ;
Soong, Weily ;
Hussain, Iftikhar ;
Foley, Peter ;
Hide, Michihiro ;
Bouaziz, Jean-David ;
Gelfand, Joel M. ;
Sher, Lawrence ;
Schuttelaar, Marie L. A. ;
Wang, Chen ;
Chen, Zhen ;
Akinlade, Bolanle ;
Gadkari, Abhijit ;
Eckert, Laurent ;
Davis, John D. ;
Rajadhyaksha, Manoj ;
Staudinger, Heribert ;
Graham, Neil M. H. ;
Pirozzi, Gianluca ;
Ardeleanu, Marius .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) :377-388
[45]   Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study [J].
Howard Jr, James F. ;
Bresch, Saskia ;
Farmakidis, Constantine ;
Freimer, Miriam ;
Genge, Angela ;
Hewamadduma, Channa ;
Hinton, John ;
Hussain, Yessar ;
Juntas-Morales, Raul ;
Kaminski, Henry J. ;
Maniaol, Angelina ;
Mantegazza, Renato ;
Masuda, Masayuki ;
Nowak, Richard J. ;
Sivakumar, Kumaraswamy ;
Smilowski, Marek ;
Utsugisawa, Kimiaki ;
Vu, Tuan ;
Weiss, Michael D. ;
Zajda, Malgorzata ;
Bloemers, Jos ;
Boroojerdi, Babak ;
Brock, Melissa ;
de la Borderie, Guillemette ;
Duda, Petra W. ;
Vanderkelen, Mark ;
Leite, M. Isabel .
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
[46]   Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study [J].
Suresh Durgam ;
William M. Greenberg ;
Dayong Li ;
Kaifeng Lu ;
Istvan Laszlovszky ;
Gyorgy Nemeth ;
Raffaele Migliore ;
Stephen Volk .
Psychopharmacology, 2017, 234 :199-209
[47]   Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study [J].
Durgam, Suresh ;
Greenberg, William M. ;
Li, Dayong ;
Lu, Kaifeng ;
Laszlovszky, Istvan ;
Nemeth, Gyorgy ;
Migliore, Raffaele ;
Volk, Stephen .
PSYCHOPHARMACOLOGY, 2017, 234 (02) :199-209
[48]   Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study [J].
Baraliakos, Xenofon ;
van der Heijde, Desiree ;
Sieper, Joachim ;
Inman, Robert Davies ;
Kameda, Hideto ;
Maksymowych, Walter Peter ;
Lagunes-Galindo, Ivan ;
Bu, Xianwei ;
Wung, Peter ;
Kato, Koji ;
Shmagel, Anna ;
Deodhar, Atul .
ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
[49]   Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study [J].
Paller, Amy S. ;
Siegfried, Elaine C. ;
Simpson, Eric L. ;
Cork, Michael J. ;
Sidbury, Robert ;
Chen, Iris H. ;
Khokhar, Faisal A. ;
Xiao, Jing ;
Dubost-Brama, Ariane ;
Bansal, Ashish .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (04) :655-668
[50]   Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study [J].
Ganesh Raghu ;
Mark J. Hamblin ;
A. Whitney Brown ;
Jeffrey A. Golden ;
Lawrence A. Ho ;
Marlies S. Wijsenbeek ;
Martina Vasakova ;
Alberto Pesci ;
Danielle E. Antin-Ozerkis ;
Keith C. Meyer ;
Michael Kreuter ;
Tracy Burgess ;
Nikhil Kamath ;
Francis Donaldson ;
Luca Richeldi .
Respiratory Research, 23